NSE மற்றும் BSE-யின் ஒவ்வொரு கார்ப்பரேட் அறிவிப்பும், AI-யால் சில நிமிடங்களில் படிக்கப்பட்டு விளக்கப்படுகிறது — தாக்கம், முக்கிய புள்ளிவிவரங்கள், குறுகிய/நீண்டகாலப் பார்வை, கவனிக்க வேண்டியவை.
குறிப்பு: இவை NSE பொது அறிக்கைகளின் AI-உருவாக்கிய, கல்வி நோக்கச் சுருக்கங்கள் — ஒவ்வொரு ஆவணத்தையும் ஆதாரமாகக் கொண்டவை, ஆனால் முதலீட்டு ஆலோசனை அல்ல, மேலும் முழுமையற்றதாகவும் இருக்கலாம். அசல் அறிக்கையுடன் சரிபார்க்கவும், செயல்படுவதற்கு முன் SEBI-பதிவு பெற்ற முதலீட்டு ஆலோசகரை அணுகவும்.
Akums Drugs Declares ₹3 Total Dividend and Announces New HR Leadership
Akums Drugs and Pharmaceuticals has recommended a combined dividend of ₹3.00 per equity share for FY26, consisting of a ₹1.00 final dividend and a ₹2.00 special dividend. The company announced a transition in senior management with Mr. V Jagannathan appointed as President – HR, replacing Mr. Arvind Srivastava. While the board approved the annual financial results, the statutory auditors highlighted an ongoing Income Tax search and seizure investigation initiated in 2025. The company has recently received a show cause notice under section 158BC, the financial impact of which is currently unascertainable.
முக்கிய அம்சங்கள்
Recommended a total dividend of ₹3.00 per share (150% of face value), including a ₹2.00 special dividend.Fixed July 3, 2026, as the record date for dividend eligibility.Appointed Mr. V Jagannathan as President – HR effective May 14, 2026.Statutory auditors issued an 'Emphasis of Matter' regarding ongoing Income Tax search and seizure proceedings.Appointed Mahajan & Aibara LLP as Internal Auditors for the 2026-27 financial year.
👀 கவனிக்க வேண்டியவை
Investors should enjoy the high dividend yield but remain cautious regarding the legal overhang from the Income Tax department's show cause notice. Monitor future disclosures for any quantified tax liabilities that may arise from the ongoing proceedings.
Akums Drugs Recommends ₹3 Total Dividend per Share and Approves FY26 Financial Results
Akums Drugs and Pharmaceuticals has approved its audited financial results for the fiscal year ended March 31, 2026. The Board has recommended a total dividend of ₹3.00 per equity share, comprising a ₹1.00 final dividend and a ₹2.00 special dividend. The record date for dividend eligibility is fixed for July 03, 2026. Notably, the auditors have highlighted an ongoing Income Tax search and seizure matter from 2025, for which the company recently received a show-cause notice.
முக்கிய அம்சங்கள்
Recommended a total dividend of ₹3.00 per share (150% of ₹2 face value), including a ₹2.00 special dividend.Fixed July 03, 2026, as the record date for dividend payment, subject to shareholder approval.Appointed Mr. V Jagannathan as President – HR (Senior Management) effective May 14, 2026.Auditors issued an 'Emphasis of Matter' regarding an Income Tax search and seizure operation and a recent show-cause notice under Section 158BC.The 22nd Annual General Meeting (AGM) is scheduled for July 10, 2026.
👀 கவனிக்க வேண்டியவை
Investors should balance the positive news of a ₹3 dividend with the regulatory risk associated with the ongoing Income Tax investigation. Monitor future disclosures regarding the show-cause notice as the financial impact is currently unascertainable.
Akums Subsidiary Acquires 4,050 Sq. Mtr Industrial Plot in Haridwar for Expansion
Akums Drugs and Pharmaceuticals' wholly-owned subsidiary, Pure and Cure Healthcare Private Limited, has executed a lease deed for an industrial plot in Haridwar, Uttarakhand. The plot measures approximately 4,050 square meters and includes both land and building. This acquisition is strategically significant as the plot is adjacent to the subsidiary's existing manufacturing facility. The move is aimed at supporting and scaling up the company's business operations in the region.
முக்கிய அம்சங்கள்
Wholly-owned subsidiary Pure and Cure Healthcare executed a lease deed for a 4,050 Sq. Mtr industrial plotThe plot is located at IIE SIDCUL, Haridwar, adjacent to the subsidiary's existing manufacturing facilityThe acquisition includes both land and building to support future business operationsThe lease deed was executed on April 28, 2026, as per the regulatory filing
👀 கவனிக்க வேண்டியவை
Investors should view this as a positive operational expansion that could lead to increased production capacity. Monitor the company's upcoming capital expenditure plans to see how this facility will be integrated into their manufacturing workflow.
Akums Drugs Reaffirmed AA (Stable) Rating; New A1+ Assigned for Rs 200 Cr Commercial Paper
ICRA has reaffirmed Akums Drugs and Pharmaceuticals' long-term rating at AA (Stable) and assigned a top-tier A1+ rating for its proposed Rs 200 crore commercial paper programme. The company maintains an exceptionally strong financial profile with a total debt-to-OPBDITA ratio of just 0.2x and cash reserves of Rs 1,654.4 crore as of September 2025. While the core CDMO business grew 7% YoY in 9M FY2026, the company continues to face margin pressure in its API and trade generics segments. A significant EUR 100 million upfront payment from a European contract has further bolstered liquidity.
முக்கிய அம்சங்கள்
ICRA reaffirmed AA (Stable)/A1+ ratings and assigned a new A1+ rating for Rs 200 crore Commercial Paper.Strong liquidity position with cash and equivalents of Rs 1,654.4 crore against a minimal debt of Rs 90.3 crore.CDMO segment generated Rs 2,533 crore in 9M FY2026, benefiting from 11% volume growth.Total Debt/OPBDITA stands at a healthy 0.2 times with an interest coverage ratio of 5.3 times.Company received EUR 100 million upfront as part of a EUR 200 million long-term contract with a European customer.
👀 கவனிக்க வேண்டியவை
The reaffirmed high credit rating and robust cash position confirm the company's financial stability and low default risk. Investors should monitor the scale-up of the export business and the potential turnaround of the loss-making API segment.
Akums Q3 FY26 Revenue Up 14.8% to ₹1,160 Cr; CDMO Segment Grows 16.3%
Akums Drugs and Pharmaceuticals reported a strong Q3 FY26 with operating revenue rising 14.8% YoY to INR 1,160 crores, primarily driven by a 16.3% growth in its core CDMO business. EBITDA grew 21% YoY to INR 147 crores, with margins expanding to 12.7% despite continued pricing pressure in the API segment. The company maintains a massive cash surplus of INR 1,573 crores and is actively evaluating M&A opportunities to complement its existing business. International branded formulations showed significant recovery, growing 120% sequentially to INR 50 crores.
முக்கிய அம்சங்கள்
Consolidated revenue increased 14.8% YoY to INR 1,160 crores, with CDMO revenue reaching INR 916 crores.Operating EBITDA rose 21% YoY to INR 147 crores, while PAT stood at INR 68 crores after a one-time labour code impact of INR 18.2 crores.International branded formulation revenue surged 120% QoQ to INR 50 crores due to demand recovery in key markets.Maintained a strong liquidity position with a cash surplus of INR 1,573 crores and free cash flow of INR 944.5 crores.European expansion is on track with EU GMP accreditation received for Plant 2 and supplies already commenced from Plant 1.
👀 கவனிக்க வேண்டியவை
Investors should monitor the company's deployment of its INR 1,573 crore cash pile for strategic acquisitions and the ramp-up of its European CDMO operations. The stock remains a strong play on the domestic outsourcing theme given its robust volume growth and margin expansion in the core CDMO segment.
📊 கடந்த 7 நாட்கள் — உணர்வு அடிப்படையில் பகுப்பாய்வு செய்யப்பட்ட அறிவிப்புகள்
Akums Q3 FY26: Revenue Up 14.8% YoY to Rs 1,160 Cr, Adj PAT Jumps 29.5%
Akums Drugs and Pharmaceuticals reported a robust Q3 FY26 performance with revenue increasing 14.8% YoY to Rs 1,160 crore. The core CDMO business grew over 16% while Adjusted EBITDA rose 21% to Rs 147 crore, reflecting improved capacity utilization and margin expansion to 12.7%. Adjusted PAT saw a significant jump of 29.5% YoY to Rs 86 crore. Additionally, the company secured key regulatory approvals from EU GMP and UK MHRA, strengthening its position for expansion into regulated global markets.
முக்கிய அம்சங்கள்
Revenue increased 14.8% YoY to Rs 1,160 Cr, driven by strong CDMO volumes and international demand.Adjusted EBITDA grew 21% YoY to Rs 147 Cr, with margins improving to 12.7% from 12.0% in Q3 FY25.Adjusted PAT surged 29.5% YoY to Rs 86 Cr, while 9M FY26 PAT reached Rs 193 Cr.Secured EU GMP certifications for two facilities and first UK MHRA approval for Rivaroxaban tablets.International branded formulation segment revenue more than doubled on a sequential basis.
👀 கவனிக்க வேண்டியவை
The strong earnings growth and regulatory breakthroughs in regulated markets like the EU and UK are positive indicators. Investors should monitor the company's ability to maintain this momentum in international markets and the turnaround in the API segment.
Akums Drugs Q3 Standalone Revenue Up 18% Q-o-Q to ₹3,656M; PAT Declines 31% Y-o-Y
Akums Drugs and Pharmaceuticals reported a standalone revenue of ₹3,656.06 million for Q3 FY26, showing a healthy sequential growth of 18.2% from Q2. However, Net Profit (PAT) at ₹281.14 million declined by 31.7% year-on-year, impacted by rising expenses and an exceptional loss of ₹38.08 million. The company has successfully utilized 100% of its ₹6,373.70 million IPO proceeds for debt repayment and working capital. Investors should remain cautious regarding the ongoing Income Tax search proceedings, which are yet to reach a final conclusion.
முக்கிய அம்சங்கள்
Standalone Revenue from operations grew 18.2% Q-o-Q to ₹3,656.06 million.Net Profit (PAT) stood at ₹281.14 million, down from ₹411.68 million in the same quarter last year.Reported an exceptional item loss of ₹38.08 million during the quarter ended December 2025.Total expenses increased to ₹3,585.35 million compared to ₹3,063.58 million in Q3 FY25.IPO proceeds of ₹6,373.70 million have been fully utilized as of December 31, 2025.
👀 கவனிக்க வேண்டியவை
Investors should monitor the company's ability to recover margins which have seen year-on-year compression despite revenue growth. The ongoing Income Tax department's search and seizure proceedings remain a key regulatory risk to track.
Akums Drugs Secures EU-GMP Certification for Two Haridwar Facilities; Valid Until 2028
Akums Drugs and Pharmaceuticals has received European GMP certifications for its Plant 1 and Plant 2 located in Haridwar from the Bulgarian Drug Agency. Plant 1 received a renewal, while Plant 2 achieved its first-ever EU-GMP certification, both valid for three years until October 2028. This milestone allows the company to export tablets, capsules, and oral liquids to EU-regulated markets and other regions following similar standards. Crucially, Plant 2 will now begin servicing a European CDMO contract that was signed in December 2024.
முக்கிய அம்சங்கள்
EU-GMP certification granted by Bulgarian Drug Agency for two Haridwar-based manufacturing plants.Plant 1 certification is a renewal, while Plant 2 receives its first-time EU-GMP approval.Certifications are valid for a 3-year period, expiring in October 2028.Plant 2 will service the European CDMO contract signed by the company in December 2024.Enables supply of tablets, capsules, sachets, and oral liquid formulations to EU regulated markets.
👀 கவனிக்க வேண்டியவை
This is a positive development that expands the company's addressable market and validates its manufacturing standards for high-margin exports. Investors should monitor the execution of the December 2024 CDMO contract as a key revenue driver.
Akums Drugs President – Finance Rajkumar Bafna Resigns Effective Dec 31, 2025
Akums Drugs and Pharmaceuticals Limited has announced the resignation of Mr. Rajkumar Bafna from his position as President – Finance, a Senior Management Personnel role. The resignation is effective from the close of business hours on December 31, 2025. Mr. Bafna cited personal health concerns specifically related to Delhi's pollution levels as the reason for his departure. The company has accepted the resignation and is managing the transition of his responsibilities.
முக்கிய அம்சங்கள்
Mr. Rajkumar Bafna, President – Finance, to step down effective December 31, 2025.The resignation was formally tendered on December 3, 2025, and accepted by the company on December 12, 2025.Departure is attributed to personal health issues linked to environmental conditions in Delhi.Mr. Bafna is categorized as Senior Management Personnel (SMP) under SEBI Listing Regulations.
👀 கவனிக்க வேண்டியவை
Investors should monitor the company's upcoming announcements regarding the appointment of a successor to ensure continuity in financial leadership. The clear personal reason provided for the resignation mitigates concerns regarding internal corporate governance issues.
⚠️இந்தத் தளம் எவ்வாறு உருவாக்கப்படுகிறது: சந்தைத் தரவுப் பக்கங்கள் NSE/BSE வெளியீடுகள் மற்றும் நிறுவனங்களின் தாக்கல்களிலிருந்து தானாகக் கணக்கிடப்படுகின்றன; செய்திக் கட்டுரைகளும் அறிவிப்புப் பகுப்பாய்வுகளும் AI உதவியுடன் எழுதப்படுகின்றன, மனித மேற்பார்வையுடன்: AI உருவாக்குவதை எங்கள் ஆசிரியர்கள் மதிப்பாய்வு செய்கின்றனர். இரண்டிலும் பிழைகள் இருக்கலாம். எந்தவொரு முதலீட்டு முடிவுக்கு முன்பும் அசல் மூலங்களில் சரிபார்க்கவும். முதலீட்டு ஆலோசனை அல்ல; Flash Finance SEBI-பதிவு பெற்றது அல்ல. நாங்கள் AI-ஐ எவ்வாறு பயன்படுத்துகிறோம்
🎁 ஆரம்பகால ஆதரவாளர்களுக்கு மட்டும் · குறுகிய கால சலுகை
எங்கள் AI பங்குச் சந்தை பகுப்பாய்வு: டெலிகிராம், வாட்ஸ்அப்பில் இலவசம்
⚡ 3500+ நிறுவனங்களை நாங்கள் உடனுக்குடன் கண்காணிக்கிறோம். NSE-யில் ஒரு நிறுவன அறிவிப்பு வெளியானதுமே, எங்கள் AI அதைப் படித்து, சுருக்கி, அதன் தாக்கத்தைச் சில நொடிகளில் உங்களுக்குச் சொல்கிறது.
இதுபோன்ற AI பகுப்பாய்வுக்குக் கட்டணத் தளங்கள் ஆண்டுக்கு ₹1,00,000-க்கும் மேல் வசூலிக்கின்றன. எங்கள் சேனல்களில் இது இலவசம்.
